Analysis
As of September 6, 2026, the total number of US IPOs this year is running only about 2.15% ahead of the same point in 2025, which had recorded 233 listings by this date, according to tracking published by Stock Analysis' 2026 IPO database and Renaissance Capital's IPO Center. That is a strikingly modest gap given how loudly 2026's headline pipeline -- Anthropic, SB Energy, Nscale, and the wave of AI infrastructure names Pulse has covered throughout the week -- has dominated financial media attention.
The Gap Between Headlines and Volume
The disconnect is straightforward once you separate deal size from deal count. A handful of potential trillion-dollar-scale listings can dominate coverage and dollar volume without moving the total NUMBER of companies going public very much, because most of 2026's IPO activity, like most years, consists of small and mid-cap listings that don't make headlines: regional banks, biotech names with a single Phase 2 readout, and micro-cap resource companies. Pulse's own coverage this week of ADARx Pharmaceuticals and the ongoing S-1 filing pipeline reflects that base layer -- it's real activity, but it's not the kind that moves an aggregate year-over-year comparison much on its own.
“## The Gap Between Headlines and Volume The disconnect is straightforward once you separate deal size from deal count.”
What Would Actually Move the Number
The pipeline megadeals, when and if they price, will move DOLLAR volume dramatically -- a single Anthropic listing at anywhere near its targeted $2 trillion valuation would likely be the largest single IPO in history by proceeds, dwarfing the combined value of dozens of smaller listings. But dollar volume and listing count are different statistics, and generalist financial coverage tends to conflate them. A healthy, broad-based IPO market needs both: mega-deals that restore investor confidence in the asset class, and a wide base of mid-size listings that indicate confidence has spread beyond a handful of trophy names.
The SPAC Signal, Revisited
Pulse noted earlier this week that new blank-check vehicle filings -- typically the market's most sentiment-sensitive indicator, since sponsors only file when they expect a listing window open six to nine months out -- have continued at a modest but steady trickle. That combined with the barely-ahead-of-2025 total count paints a market that is optimistic at the top (the megadeals) and merely stable, not accelerating, in the broad middle.
What This Means for Founders Weighing a 2027 Listing
For a company evaluating whether 2027 is the right listing year, the practical read is that megadeal enthusiasm at the top of the market doesn't necessarily mean the window is wide open for mid-size companies -- underwriters and institutional investors have shown they'll pay up for scarcity value on trophy assets while remaining selective everywhere else. The number worth tracking through year-end is whether the count gap over 2025 widens meaningfully once the Anthropic and SB Energy listings actually price, since a successful pricing on either could pull forward investor appetite for the mid-size names currently sitting in the S-1 pipeline.
